Innovative R&D Portfolio ZIVO Bioscience's extensive proprietary algal and bacterial strains, along with their bioactive molecules and patented technologies, present opportunities to collaborate or supply ingredients for novel therapeutic, nutraceutical, and animal health products targeting health-conscious and biotech-focused markets.

Recent Strategic Partnerships The company's recent partnership with the University of Delaware to combat Avian Influenza highlights its capacity for collaborative R&D, signaling potential for strategic alliances in zoonotic diseases and poultry health sectors, attracting partners in veterinary and food safety industries.

Financial Stability & Growth With reported revenue between one to ten million dollars and an active investment profile, ZIVO presents opportunities for early-stage funding, licensing, or partnership deals to accelerate product development and commercialization efforts.

Market Engagement Activities Participation in industry events like The Microcap Conference 2025 offers avenues for outreach to investors, strategic partners, and clients interested in biotech innovations, providing potential leads for licensing and joint ventures.

Sustainability & Future Focus ZIVO’s focus on biologically active molecules derived from algae and bacteria aligns with the growing market trend toward sustainable, plant-based, and eco-friendly health products, presenting opportunities for brands emphasizing sustainability and natural formulations.